Scribe Therapeutics is a molecular engineering company focused on creating best-in-class in vivo therapies that permanently treat the underlying cause of disease. Founded by CRISPR inventors and leading molecular engineers Benjamin Oakes, Brett Staahl, David Savage, and Jennifer Doudna, Scribe is overcoming the limitations of current genome editing technologies by developing custom engineered enzymes and delivery modalities as part of a proprietary, evergreen CRISPR by Design™ platform for CRISPR-based genetic medicine.

We are seeking a highly passionate and motivated toxicologist to join us in our quest to bring the next generation of CRISPR-based therapeutics into IND enabling framework. The current role is for aDirector/Senior Directory of Toxicology. The candidate should have a passion for managing safety pharmacology and toxicology aspects of the IND enabling studies that will bring gene editing modalities into first-in-human study.

The candidate will have numerous opportunities for professional growth in a rapidly growing biotechnology start-up, which includes growing into a cross-functional leadership role of increasing responsibilities that spans across the pipeline, and the ability to publish highly impactful work in peer reviewed journals. 

Key Responsibilities:

• Lead the effort and manage nonclinical safety pharmacology and toxicology studies across all Scribe development programs
• Serve as a core project team member representing toxicology/safety on multi-disciplinary project teams facilitating development of gene editing therapies
• Define and mitigate nonclinical safety findings, and assess the relevance of toxicological findings to safety in human
• Identify and leverage external experts in potential findings related to nonclinical safety assessment
• Author toxicology summaries for regulatory submissions 
• Assist in building of high performing team by instilling a culture of scientific rigor, open debate, collaborative teamwork, sense of accountability

Required Skills and Background:

• PhD degree in toxicology, pharmacology, or related discipline and 3+years of industry-related experience; or MS degree in a related discipline and 5+ years of experience 
• Minimum of 3 years of industry experience in all aspects of preclinical safety assessment including genotoxicity, general toxicology, developmental and reproductive toxicology, and safety pharmacology 
• Knowledge of regulatory requirements and expectations for nonclinical packages to support first in human clinical study
• Enthusiasm for working with novel therapeutic modalities and lead teams to address safety issues
• Experience in gene therapy and/or cardiovascular/liver disease field is desirable but not necessary
• Demonstrated knowledge of general regulatory requirements and expectations for nonclinical safety assessment packages to support first in human study
• Excellent communication skills with an ability to communicate across a variety of high-level stake holders
• Strong attention to detail, experience in monitoring work to assure quality, accuracy, and thoroughness

Salary will be commensurate with experience. We will provide an intellectually stimulating, collegial and fast-paced environment. If you are ready to join our team of engineers and carve the future of therapeutics, then we are excited to hear from you! Visit us at www.scribetx.com.  

We are committed to creating a diverse environment and are proud to be an equal opportunity employer. All qualified applicants will receive consideration for employment without regard to race, color, religion, gender, gender identity or expression, sexual orientation, national origin, disability, age, or veteran status.